![]() |
市场调查报告书
商品编码
1715190
2031年亚太地区液体切片采血管市场预测-区域分析-依产品、材料、应用及最终用户Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Regional Analysis - by Product, Material, Application, and End User |
2023年亚太地区液体切片采血管市场价值为287.4623亿美元,预计2031年将达到1161.6956亿美元;预计2023年至2031年的复合年增长率为19.1%。
液体活检在癌症监测中的应用推动了亚太地区液体活检采血管市场的发展
人们越来越关注采用液体活检程序来监测癌症生长、检测基因突变、识别復发迹像以及预测对免疫疗法的敏感性。早期发现癌症可带来更好的治疗效果;例如,早期发现的癌症患者的缓解率和存活率比晚期或恶性癌症患者更高。然而,在症状不明显的早期阶段进行一系列放射学检测或侵入性癌症监测程序来检测癌症是不切实际的。液体活检使得透过常规抽血或尿液分析进行定期癌症筛检成为可能。它可以识别高度特异性和循环标记物,以用于早期癌症检测。
液体活检程序也用于癌症患者的治疗后监测。治疗后癌细胞仍可能在体内持续存在,但其水平低于影像学研究的分辨率和检测水平;这种状况被称为微小残留疾病。这种疾病被认为是癌症缓解的主要原因。与癌症筛检和早期检测类似,液体活检的临床应用受到目前测试的敏感性和特异性的限制。然而,由于这种敏感性限制,液体活检技术可用于检测实体肿瘤而非血癌的微小残留疾病。借助液体活检,医疗保健专业人员可以监测癌症復发的情况,然后透过正确的诊断儘早治疗。
最初对特定酪胺酸激酶抑制剂(包括吉非替尼、厄洛替尼、克唑替尼和色瑞替尼)敏感的肿瘤经常发生变异并对这些药物产生抗药性。液体切片检查可以检测肿瘤状态的变化,并帮助医生修改治疗策略,以避免患者体内对任何药物产生抗药性。因此,液体活检可以早期发现癌症并帮助医疗保健专业人员确定确切的治疗方案。此外,它还有助于监测治疗过程以及治疗后患者的状况。因此,人们越来越关注液体活检在癌症患者监测中的应用,这可能会在预测期内对液体活检程序的采血管产生大量需求。
亚太地区液体切片采血管市场概况
亚太地区液体切片采血管市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。由于该地区癌症患者数量激增,对采血管的需求也增加。此外,政府加强医疗保健基础设施和支持研究的倡议预计将在预测期内为市场成长创造重大机会。在中国,政府对医疗基础设施的大量投资以及对提供强化医疗服务的重视使液体活检采血管市场受益。癌症病例的增加也促进了市场的成长,因为这表明对液体活检等复杂诊断工具的需求增加。 2017 年 5 月,Streck 与中国综合分子诊断分销商 GenomePrecision Technology 签署了分销协议,分销其细胞稳定、分子、尿液分析和流式细胞术产品。无细胞 DNA BCT 和无细胞 RNA BCT(皆可稳定有核血细胞)以及无细胞 DNA 尿液保存剂皆属于 Streck 的细胞稳定产品。这表明中国的主要市场参与者专注于加强其产品管道,以抓住该国市场的成长机会。此外,Vazyme Biotech 和 CNWTC 等生技公司也提供 cfDNA 管、液体切片试剂盒、药物研发、分子研究等产品。
亚太地区液体切片采血管市场收入及预测(2031年)(百万美元)
亚太地区液体切片采血管市场细分
亚太地区液体切片采血管市场依产品、材料、应用、最终用户、国家分类。
根据产品,亚太地区液体切片采集血管市场分为 ccfDNA/cfDNA 管、cfRNA 管、CTC 管、gDNA 管、细胞内 RNA 管等。 2023 年,ccfDNA/cfDNA 管细分市场占据亚太地区液体活检采血管市场最大份额。
从材质来看,亚太地区液体切片采集血管市场分为塑胶和玻璃。 2023 年,塑胶部分在亚太地区液体活检采血管市场中占有较大份额。
根据应用,亚太地区液体切片采集血管市场分为体外诊断(IVD)和研究。 2023 年,体外诊断 (IVD) 领域在亚太地区液体活检采血管市场中占据较大份额。
就最终用户而言,亚太地区液体切片采血管市场分为基因诊断实验室、研发中心、传统诊断中心等。 2023 年,基因诊断实验室部门占据亚太地区液体活检采血管市场的最大份额。
根据国家/地区,亚太地区液体活检采血管市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2023 年,中国占据亚太地区液体切片采血管市场最大份额。
Biocept公司;精确科学公司; F.霍夫曼-罗氏有限公司; Greiner Bio-One International GmbH; MagBio Genomics 公司; Norgen Biotek 公司; QIAGEN NV;斯特雷克公司;和 Zymo Research Corporation 是亚太地区液体活检采血管市场领先的公司之一。
The Asia Pacific blood collection tubes for liquid biopsy market was valued at US$ 28,746.23 million in 2023 and is expected to reach US$ 1,16,169.56 million by 2031; it is estimated to register a CAGR of 19.1% from 2023 to 2031.
Use of Liquid Biopsy in Cancer Monitoring Boosts Asia Pacific Blood Collection Tubes for Liquid Biopsy Market
There is a growing focus on employing liquid biopsy procedures for monitoring cancer growth, detecting genetic mutations, identifying signs of relapse, and predicting sensitivity to immunotherapy. The early detection of cancer results in better outcomes; for example, patients with early detection show higher remission and survival rates than those with late-stage or malignant cancer. However, it is impractical to perform serial radiological testing or invasive procedures for cancer surveillance to detect cancer in the early stages when symptoms are not evident. Liquid biopsy unlocks the possibility of periodic cancer screening through routine blood draws or urinalyses. It can identify highly specific and circulating markers for early cancer detection.
Liquid biopsy procedures are also employed for post-treatment monitoring of cancer patients. Cancer cells may persist in the body after treatment at levels below the resolution and detection levels of imaging studies; the condition is termed a minimal residual disease. This disease is considered a principal cause of cancer remission. Similar to that in cancer screening and early detection, the clinical application of liquid biopsy is limited by the sensitivity and specificity of current tests. However, due to this sensitivity limitation, liquid biopsy techniques can be used for detecting minimal residual disease for solid tumors than blood cancers. With the help of liquid biopsy, the healthcare professional can monitor the case of reoccurrence of cancer, which can then be treated early with the help of proper diagnosis.
Tumors that are initially susceptible to specific tyrosine kinase inhibitors, including gefitinib, erlotinib, crizotinib, and ceritinib, often mutate and develop resistance to these drugs. Liquid biopsy detects the changes in the tumor status and helps doctors modify the treatment strategies to avoid the development of resistance to any medication in the patient's body. Thus, liquid biopsy allows the early detection of cancer and helps healthcare professionals determine the exact course of action for treatment. In addition, it helps monitor treatments and the condition of the patient after the treatment. Thus, there is an increase in focus on the use of liquid biopsy in the monitoring of cancer patients, which is likely to create a significant demand for blood collection tubes for liquid biopsy procedures during the forecast period.
Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Overview
The Asia Pacific blood collection tube for liquid biopsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The demand for blood collection tubes is increasing due to an upsurge in the number of cancer patients in the region. Moreover, government initiatives to enhance healthcare infrastructure and support research studies are expected to create significant opportunities for market growth during the forecast period. In China, significant government investments in healthcare infrastructure and emphasis on providing enhanced medical services benefit the blood collection tubes for liquid biopsy market. The increasing number of cancer cases is also contributing to the market growth, as it indicates the elevated need for sophisticated diagnostic tools such as liquid biopsies. In May 2017, Streck signed a distribution agreement with GenomePrecision Technology, an integrated molecular diagnostics distributor in China, for its cell stabilization, molecular, urinalysis, and flow cytometry products. Cell-Free DNA BCT and Cell-Free RNA BCT (both stabilize nucleated blood cells), and Cell-Free DNA Urine Preserve are among Streck's cell stabilization products. This signifies that key market players in China focus on enhancing their product access to grab growth opportunities in the market in this country. Further, biotechnology companies such as Vazyme Biotech and CNWTC offer products for cfDNA tubes, liquid biopsy kits, drug discovery, molecular research, and more.
Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Segmentation
The Asia Pacific blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
By application, the Asia Pacific blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
Based on country, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China segment held the largest share of Asia Pacific blood collection tubes for liquid biopsy market in 2023.
Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the Asia Pacific blood collection tubes for liquid biopsy market.